Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study

•Better clinical responses to teclistamab correlate with a more functional initial immune T-cell repertoire in the periphery and tumor site.•More durable responses to teclistamab associate with lower Tregs and lower expression of inhibitory receptors on T cells at baseline.